全基因组关联分析和门德尔随机化蛋白质组学确定了心力衰竭的药物标
Danielle Rasooly1,2, Gina M Peloso3,4, Alexandre C Pereira5,6
1Division of Aging, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA, 02130, USA. drasooly@bwh.harvard.edu.
Nature communications
|July 10, 2023
概括
这项大型遗传研究通过分析超过100万名个体,确定了心力衰竭 (HF) 的新风险因素. 发现七种蛋白质是预防心力衰竭的潜在目标.
科学领域:
- 遗传学 遗传学 是一个
- 心血管疾病 心血管疾病
- 蛋白质组学是指蛋白质组学.
背景情况:
- 心力衰竭 (HF) 是一个主要的全球健康负担,具有复杂的遗传基础.
- 全基因组关联研究 (GWAS) 已经确定了许多HF的遗传风险位置,但对因果途径的全面理解仍然不完整.
研究的目的:
- 通过对GWAS进行大规模的元分析,确定心力衰竭的新型遗传决定因素.
- 通过使用孟德尔的随机化和局部化分析,研究人类蛋白质在心力衰竭病原发生的因果作用.
- 为了确定潜在的治疗目标,用于心力衰竭的初级预防.
主要方法:
- 对全基因组关联研究 (GWAS) 的元分析,包括超过9万例心力衰竭病例和100万名欧洲祖先的对照.
- 门德尔的随机化和局部化分析将GWAS总结统计与血液蛋白质定量特征位置 (pQTLs) 整合在一起.
- 基因cis-only局部化分析以确定可能的因果基因.
主要成果:
- 确定了39种全基因组显著的心力衰竭风险变异,其中18种是新发现.
- 通过孟德尔的随机化-蛋白质组学发现了10个额外的假定导致心力衰竭的基因.
- 确定了七种特定蛋白质 (CAMK2D,PRKD1,PRKD3,MAPK3,TNFSF12,APOC3和NAE1) 作为潜在的治疗标.
结论:
- 这项研究显著扩大了已知的心力衰竭遗传风险因素的范围.
- 门德尔的随机化-保护学为特定蛋白质在心力衰竭发展中的因果作用提供了有力的证据.
- 这些已识别的蛋白质代表了针对初级预防心力衰竭的新型治疗干预措施的有希望的目标.
相关概念视频
01:11Genome-wide Association Studies-GWAS
13.6K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.6K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
465
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
465
01:30Heart Failure V: Medical Management
14
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
14
02:46Genetic Screens
5.0K
Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
5.0K
01:29Heart Failure II: Pathophysiology
16
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
16